SAN DIEGO, April 14 (Reuters) - Combining a low dose of a targeted cancer-fighter with an anti-inflammatory drug reduces the risk of recurring colorectal polyps, an early sign of colon cancer, by as much as 95 percent, researchers said on Monday. A study conducted by the University of California, Irvine, also found that the drug combination was much less toxic than chemotherapy.
